We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.52B
AUM Growth
+$387M
Cap. Flow
+$192M
Cap. Flow %
7.6%
Top 10 Hldgs %
45.8%
Holding
129
New
32
Increased
30
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.4M
2
ABBV icon
AbbVie
ABBV
+$31.2M
3
AGN
Allergan plc
AGN
+$24M
4
BAX icon
Baxter International
BAX
+$22.3M
5
GILD icon
Gilead Sciences
GILD
+$20.2M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$59.8M
2
AGN
Allergan Inc
AGN
+$48.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.5M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$22.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 80.13%
2 Real Estate 3.95%
3 Financials 1.4%
4 Industrials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYH icon
101
CALL
Community Health Systems
CYH
$391M
$2.61M 0.1%
+60,500
New +$2.51M
IMMU
102
DELISTED
Immunomedics Inc
IMMU
$1.92M 0.08%
+500,000
New +$2.17M
CARM
103
DELISTED
Carisma Therapeutics
CARM
$1.75M 0.07%
9,798
-20,712
-68% -$4.53M
SRNE
104
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.65M 0.07%
142,597
-71,299
-33% -$825K
SRPT icon
105
CALL
Sarepta Therapeutics
SRPT
$1.64B
$1.53M 0.06%
+115,100
New +$1.53M
BLCM
106
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.39M 0.06%
6,000
– –
CLLS
107
Cellectis
CLLS
$287M
$1.38M 0.05%
+40,000
New +$1.45M
SAGE
108
DELISTED
Sage Therapeutics
SAGE
$753K 0.03%
15,000
+10,000
+200% +$430K
LRMR icon
109
Larimar Therapeutics
LRMR
$398M
$527K 0.02%
1,109
-1,109
-50% -$526K
MGNX icon
110
MacroGenics
MGNX
$240M
$400K 0.02%
12,743
– –
XNCR icon
111
Xencor
XNCR
$1.59B
$306K 0.01%
+20,000
New +$316K
ACHV icon
112
Achieve Life Sciences
ACHV
$647M
$243K 0.01%
51
– –
AMGN icon
113
CALL
Amgen
AMGN
$209B
– –
-285
Closed -$45K
JAZZ icon
114
CALL
Jazz Pharmaceuticals
JAZZ
$16.2B
– –
-281
Closed -$46K
LGND icon
115
Ligand Pharmaceuticals
LGND
$5.94B
– –
-110,928
Closed -$3.68M
LLY icon
116
Eli Lilly
LLY
$1.03T
– –
-186,918
Closed -$12.9M
LITS
117
Lite Strategy Inc
LITS
$33.6M
– –
-12,196
Closed -$1.04M
PTCT icon
118
PTC Therapeutics
PTCT
$6.26B
– –
-119,150
Closed -$6.17M
REGN icon
119
CALL
Regeneron Pharmaceuticals
REGN
$77.4B
– –
-112
Closed -$46K
EIGR
120
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,348
Closed -$11.8M
CLVS
121
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-51
Closed -$3K
DRNA
122
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-156,250
Closed -$2.57M
NPSP
123
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-625,900
Closed -$22.4M
SHPG
124
DELISTED
Shire pic
SHPG
– –
-281,522
Closed -$59.8M
AGN
125
DELISTED
Allergan Inc
AGN
– –
-228,227
Closed -$48.5M
1 2 3 4
5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Tekla Capital Management held 129 positions worth $2.52B, up 18% from $2.14B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Tekla Capital Management deployed $192M of net new capital in Q1 2015, opening 32 new positions and adding to 30 existing holdings. Its largest new stake was Baxter International: 588,384 shares worth $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $28.5M trimmed.

  • Tekla Capital Management's largest Q1 2015 buy was Baxter International: 588,384 shares worth $21.9M.
  • Tekla Capital Management added most to Teva Pharmaceuticals in Q1 2015, an estimated $33.4M increase.
  • Tekla Capital Management's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $28.5M.
  • Tekla Capital Management fully exited Shire pic in Q1 2015, selling an estimated $59.8M.
  • Tekla Capital Management's ten largest holdings make up 46% of its $2.52B portfolio in Q1 2015.
  • Tekla Capital Management opened 32 new positions and closed 13 in Q1 2015.
  • Tekla Capital Management's portfolio value rose 18% quarter-over-quarter to $2.52B.

Based on Tekla Capital Management's 13F filing for Q1 2015, filed 6 May 2015.